Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics, Inc. (VRDN)
:VRDN
VRDN Analyst Ratings
Strong Buy
9 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
VRDN Stock 12 Month Forecast
Average Price Target
$41.11
▲(169.40% Upside)
| Highest Price Target$50.00 | Average Price Target$41.11 | Lowest Price Target$27.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
Reiterated
02/28/25
Leerink Partners
Reiterated
02/27/25
LifeSci Capital
Reiterated
02/27/25
Wells Fargo
Reiterated
02/27/25
RBC Capital
Reiterated
02/27/25
Wedbush
Reiterated
02/27/25
Needham
Reiterated
02/27/25
TD Cowen
Reiterated
02/27/25
JMP Securities
Reiterated
02/27/25
Stifel Nicolaus
Reiterated
02/10/25
Oppenheimer
$28
Buy
83.49%
Upside
Reiterated
12/17/24
Viridian Therapeutics (VRDN) Gets a Buy from Oppenheimer
Unknown Analyst
Not Ranked
Evercore ISI
$41
Buy
168.68%
Upside
Assigned
12/17/24
We wish mgmt. showed the proptosis/diplopia data specifically in the baseline CAS0/1 subgroup to definitively address this point, but did note on the call that benefit on both measures was independent of CAS response – which is a clear positive. Even if some investors remain skeptical and want to see this full data, the point remains that VRDN clearly has this as an (on label) marketing advantage over Tepezza (in addition to infusion time, # cycles). Point #2) safety, mainly hearing events, is solid and largely in line with THRIVE We continue to focus most on hearing impairments, since that has the most readthrough to long T1/2 subQ 003. Pbo came
BTIG
$61
Buy
299.74%
Upside
Reiterated
12/16/24
Promising Clinical Data and Strategic Advances Propel Buy Rating for Viridian Therapeutics
Goldman Sachs
$31→$35
Buy
129.36%
Upside
Reiterated
11/13/24
Viridian Therapeutic (VRDN) PT Raised to $35 at Goldman SachsGoldman Sachs analyst Richard Law raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $35.00 (from $31.00) while maintaining a Buy rating.
Jefferies
$45
Buy
194.89%
Upside
Assigned
11/13/24
Jefferies Releases a Buy Rating on Viridian Therapeutics (VRDN)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
Reiterated
02/28/25
Leerink Partners
Reiterated
02/27/25
LifeSci Capital
Reiterated
02/27/25
Wells Fargo
Reiterated
02/27/25
RBC Capital
Reiterated
02/27/25
Wedbush
Reiterated
02/27/25
Needham
Reiterated
02/27/25
TD Cowen
Reiterated
02/27/25
JMP Securities
Reiterated
02/27/25
Stifel Nicolaus
Reiterated
02/10/25
Oppenheimer
$28
Buy
83.49%
Upside
Reiterated
12/17/24
Viridian Therapeutics (VRDN) Gets a Buy from Oppenheimer
Unknown Analyst
Not Ranked
Evercore ISI
$41
Buy
168.68%
Upside
Assigned
12/17/24
We wish mgmt. showed the proptosis/diplopia data specifically in the baseline CAS0/1 subgroup to definitively address this point, but did note on the call that benefit on both measures was independent of CAS response – which is a clear positive. Even if some investors remain skeptical and want to see this full data, the point remains that VRDN clearly has this as an (on label) marketing advantage over Tepezza (in addition to infusion time, # cycles). Point #2) safety, mainly hearing events, is solid and largely in line with THRIVE We continue to focus most on hearing impairments, since that has the most readthrough to long T1/2 subQ 003. Pbo came
BTIG
$61
Buy
299.74%
Upside
Reiterated
12/16/24
Promising Clinical Data and Strategic Advances Propel Buy Rating for Viridian Therapeutics
Goldman Sachs
$31→$35
Buy
129.36%
Upside
Reiterated
11/13/24
Viridian Therapeutic (VRDN) PT Raised to $35 at Goldman SachsGoldman Sachs analyst Richard Law raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $35.00 (from $31.00) while maintaining a Buy rating.
Jefferies
$45
Buy
194.89%
Upside
Assigned
11/13/24
Jefferies Releases a Buy Rating on Viridian Therapeutics (VRDN)
Best Analysts Covering Viridian Therapeutics
Which Analyst Should I Follow If I Want to Buy VRDN and Sell After:
1 Month
xxx
Success Rate
13/28 ratings generated profit
Average Return
+4.41%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 46.43% of your transactions generating a profit, with an average return of +4.41% per trade.
3 Months
xxx
Success Rate
12/23 ratings generated profit
Average Return
+1.84%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 52.17% of your transactions generating a profit, with an average return of +1.84% per trade.
1 Year
Success Rate
18/39 ratings generated profit
Average Return
-2.55%
reiterated a buy rating 26 days ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of -2.55% per trade.
2 Years
xxx
Success Rate
12/28 ratings generated profit
Average Return
-11.78%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of -11.78% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
VRDN Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Strong Buy
32
31
28
30
24
Buy
4
5
4
5
5
Hold
2
1
1
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
38
37
33
36
31
Each month's total comprises the sum of three months' worth of ratings.
VRDN Financial Forecast
VRDN Stock Forecast FAQ
What is VRDN’s average 12-month price target, according to analysts?
Based on analyst ratings, Viridian Therapeutics, Inc.’s 12-month average price target is $41.11.
What is VRDN’s upside potential, based on the analysts’ average price target?
Viridian Therapeutics, Inc. has 169.40% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is VRDN a Buy, Sell or Hold?
Viridian Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
What is Viridian Therapeutics, Inc.’s price target?
The average price target for Viridian Therapeutics, Inc. is $41.11. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $27.00. The average price target represents 169.40% Increase from the current price of $15.26.
The highest analyst price target is $50.00 ,the lowest forecast is $27.00. The average price target represents 169.40% Increase from the current price of $15.26.
What do analysts say about Viridian Therapeutics, Inc.?
Viridian Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of VRDN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.